Related Experiment Video
Updated: Aug 3, 2026
06:03
Electrolytic Inferior Vena Cava Model (EIM) of Venous Thrombosis
Published on: July 12, 2011
Dysfunctional antithrombin III in sick premature infants
Pediatric Research
|February 1, 1985
Summary
Sick premature infants may have dysfunctional antithrombin III (ATIII). This protein, crucial for blood coagulation, shows reduced biological activity in sick premature infants after the first week of life and in those with disseminated intravascular coagulation.
Area of Science:
- Biochemistry
- Neonatal Medicine
- Hematology
Background:
- Antithrombin III (ATIII) is a key inhibitor of coagulation factors.
- Human infants, particularly premature ones, exhibit lower immunological levels of ATIII.
- The functional capacity of ATIII in sick premature infants remains incompletely understood.
Purpose of the Study:
- To assess the functional status of the antithrombin III molecule in sick premature infants.
- To compare ATIII functionality across different infant groups and adult controls.
- To investigate potential molecular dysfunction in ATIII in specific neonatal conditions.
Main Methods:
- Collected plasma samples from adult controls, healthy full-term infants, sick premature infants (day 1 and >7 days), and infants with disseminated intravascular coagulation (DIC).
- Measured plasma antithrombin III levels using both biological (chromogenic substrate S2238) and immunological (radial immunodiffusion) assays.
- Analyzed ATIII functionality via biologic/immunologic ratios and performed crossed immunoelectrophoresis to assess molecular integrity.
Main Results:
- Antithrombin III biologic/immunologic ratios were near unity in adults, healthy full-term infants, and sick premature infants on day 1.
- Sick premature infants beyond the first week of life and those with DIC showed significantly lower biologic activity relative to immunological levels (B/I ratios < 1).
- Crossed immunoelectrophoresis indicated a normal ATIII molecular structure in most infants, with one exception in the DIC group.
Conclusions:
- Sick premature infants may develop a dysfunctional antithrombin III molecule during the postnatal period.
- Impaired ATIII function is evident in sick premature infants after the first week and in those with DIC.
- Further investigation into the clinical implications of dysfunctional ATIII in neonates is warranted.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:22Development of Immunocompetence
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...